Literature DB >> 6460319

A molecular model of plasmic degradation of crosslinked fibrin.

C W Francis, V J Marder.   

Abstract

Based on structural studies of both degrading insoluble crosslinked fibrin and of soluble derivatives, we have developed a model to explain the principal structural and physical features of plasmic degradation for crosslinked fibrin in vitro from the completely intact matrix to terminally degraded soluble derivatives. Plasmic digestion is viewed as a continuous process of proteolytic attack on accessible, enzyme-susceptible sites; but the process is separated into four phases based on solubility characteristics of the degrading fibrin matrix and on the structures of the soluble derivatives. The critical event of solubilization occurs only as the result of coincident cleavages at complementary sites in the basic two-stranded half-staggered overlap fibrin structure, resulting in the release of two-stranded complexes held together by noncovalent forces. The four smallest complexes which are released into solution have structures corresponding to DD/E, DY/YD, YY/DXD, and YXD/DXY. The protein initially solubilized has a constant composition with a predominance of large derivatives which are composed of at least on fragment from each of the two strands of the protofibril. Following their release into solution the larger complexes are converted in vitro to smaller ones by the continued action of plasmin, so that the complex found following prolonged digestion is DD/E. It is proposed that this newly defined group of complexes [11] represents the major form of circulating plasmic derivatives of crosslinked fibrin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460319     DOI: 10.1055/s-2007-1005040

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  3 in total

1.  Comparison of an immunochemical assay for plasma fibrinogen and a turbidimetric thrombin clotting technique to discriminate hyperlipidaemic patients from healthy controls.

Authors:  M L Knapp; M D Feher; H Carey; P D Mayne
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

2.  Interaction of amorphous calcium phosphate with fibrin in vitro causes decreased fibrinolysis and altered protease profiles: implications for atherosclerotic disease.

Authors:  G S Makowski; M L Ramsby
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

3.  Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.

Authors:  Jason R McCarthy; Irina Y Sazonova; S Sibel Erdem; Tetsuya Hara; Brian D Thompson; Purvish Patel; Ion Botnaru; Charles P Lin; Guy L Reed; Ralph Weissleder; Farouc A Jaffer
Journal:  Nanomedicine (Lond)       Date:  2012-02-21       Impact factor: 5.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.